FAM83D expression based on
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison Statistical significance Normal-vs-Primary 1.574930E-04
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer stage information is not available for 3 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Stage1
2.711400E-01
Normal-vs-Stage2
3.767700E-04
Normal-vs-Stage3
2.558400E-01
Normal-vs-Stage4
1.688980E-01
Stage1-vs-Stage2
4.166200E-01
Stage1-vs-Stage3
4.725400E-01
Stage1-vs-Stage4
9.253800E-01
Stage2-vs-Stage3
8.982300E-03
Stage2-vs-Stage4
2.180000E-01
Stage3-vs-Stage4
3.523400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient race information is not available for 5 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Caucasian
5.220000E-04
Normal-vs-AfricanAmerican
7.665700E-02
Normal-vs-Asian
2.216200E-01
Caucasian-vs-AfricanAmerican
2.605200E-01
Caucasian-vs-Asian
6.564600E-01
AfricanAmerican-vs-Asian
4.486800E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient gender information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Male
1.73687999999173E-05
Normal-vs-Female
3.032100E-02
Male-vs-Female
6.145200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient age information is not available for 1 sample.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Age(21-40Yrs)
5.837400E-01
Normal-vs-Age(41-60Yrs)
3.841500E-04
Normal-vs-Age(61-80Yrs)
1.163530E-02
Normal-vs-Age(81-100Yrs)
9.017900E-03
Age(21-40Yrs)-vs-Age(41-60Yrs)
1.010070E-02
Age(21-40Yrs)-vs-Age(61-80Yrs)
3.628100E-02
Age(21-40Yrs)-vs-Age(81-100Yrs)
1.983980E-01
Age(41-60Yrs)-vs-Age(61-80Yrs)
9.178200E-01
Age(41-60Yrs)-vs-Age(81-100Yrs)
7.020800E-01
Age(61-80Yrs)-vs-Age(81-100Yrs)
6.910000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Drinking status is not available for 80 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Non Drinker
3.384000E-04
Normal-vs-Daily Drinker
3.224500E-04
Normal-vs-Weekly Drinker
7.222100E-02
Normal-vs-Occasional Drinker
2.465600E-02
Normal-vs-Social Drinker
2.528400E-01
Non Drinker-vs-Daily Drinker
1.173590E-01
Non Drinker-vs-Weekly Drinker
1.623190E-01
Non Drinker-vs-Occasional Drinker
2.949600E-01
Non Drinker-vs-Social Drinker
3.183000E-01
Daily Drinker-vs-Weekly Drinker
2.795400E-01
Daily Drinker-vs-Occasional Drinker
9.090200E-01
Daily Drinker-vs-Social Drinker
3.736400E-01
Weekly Drinker-vs-Occasional Drinker
3.127200E-01
Weekly Drinker-vs-Social Drinker
6.178600E-01
Occasional Drinker-vs-Social Drinker
3.835000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma
Subtype descriptions Grade 1 Well differentiated (low grade)
Grade 2 Moderately differentiated (intermediate grade) Grade 3 Poorly differentiated (high grade)
Grade 4 Undifferentiated (high grade)
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Grade 1
2.084800E-01
Normal-vs-Grade 2
7.998000E-01
Normal-vs-Grade 3
6.453000E-01
Normal-vs-Grade 4
1.000000E+00
Grade 1-vs-Grade 2
1.489450E-01
Grade 1-vs-Grade 3
4.422800E-01
Grade 1-vs-Grade 4
2.084800E-01
Grade 2-vs-Grade 3
2.432200E-01
Grade 2-vs-Grade 4
7.998000E-01
Grade 3-vs-Grade 4
6.453000E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Diabetes status information is not available for 30 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Diabetic
1.650410E-01
Normal-vs-NonDiabetic
7.62600000037139E-07
Diabetic-vs-NonDiabetic
5.470400E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Pancreatitis status is not available for 39 samples.
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-Pancreatitis
2.406800E-01
Normal-vs-NoPancreatitis
2.35670000181543E-08
Pancreatitis-vs-NoPancreatitis
3.196200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Nodal metastais status is not available for 1 sample and cancer in nearby lymph nodes cannot be measured (NX) in 4 samples.
pathologic_N descriptions N0 No regional lymph node metastasis
N1 Metastases in 1 to 3 axillary lymph nodes N2 Metastases in 4 to 9 axillary lymph nodes
N3 Metastases in 10 or more axillary lymph nodes
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-N0
5.554100E-04
Normal-vs-N1
2.496300E-03
N0-vs-N1
2.489200E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
PAAD : Pancreatic adenocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Whole exome sequencing data is not available for 3 samples.
TP53 mutation status is obtained from TCGA whole exome sequencing data. We downloaded Mutation Annotation Format (MAF) files (derived from VarScan2) from Genomic Data Commons portal. The sample with/without TP53 mutation were matched with RNA-seq data
Show statistics
Hide statistics
Comparison Statistical significance
Normal-vs-TP53-Mutant
1.430340E-02
Normal-vs-TP53-NonMutant
5.172400E-04
TP53-Mutant-vs-TP53-NonMutant
2.751600E-01
Pan-cancer view
Methylation
Survival
Correlated genes
DepMap
